Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs TG Therapeutics Inc (TGTX) Price & Performance

Barclays PLCTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs TG Therapeutics Inc — how do they compare? Barclays PLC trades at $28.04 (market cap $93.87B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Barclays PLC is far larger — about 12.3× TG Therapeutics Inc's market cap, and Barclays PLC pays a 2.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

BCSTGTX
Market Cap
$93.87B$7.64B
Sector
FinancialsHealth
52-Week High
$28.56$59.06
52-Week Low
$19.36$26.94
Dividend Yield
2.19%
Enterprise Value
$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $28.09, up 0.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a low P/E of 10.68 and P/B of 0.88, indicating potential undervaluation. Revenue grew to $29.14B in 2025, with net income margin at 25.51%, though cash flow volatility from 2023-2024 remains a concern. Recent news highlights a securities investigation and mixed analyst views post-Q2 results.

Outlook is cautiously optimistic due to valuation appeal and earnings strength, but risks include legal scrutiny and cost pressures. Analyst consensus is 68% buy, with sentiment tempered by near-term headwinds. The stock offers value if operational efficiency improves, yet investors should monitor the class-action probe and expense trends.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX